Drug Trial Radar · NCT04256174
A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Aug 17, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Jun 15, 2020
Primary completion
Oct 29, 2021
Study completion Oct 29, 2021
Sponsor
- Lead sponsor
- Akesobio Australia Pty LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A dose escalation, first-in-human study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of AK120 in healthy subjects and subjects with moderate- to- severe atopic dermatitis
Conditions
- Atopic Dermatitis
Interventions
AK120 or placebo- Part 1- Cohort 1Drug
Single dose of 15mg AK120 or placebo is administered subcutaneously to healthy subjects
AK120 or placebo- Part 1- Cohort 2Drug
Single dose of 50mg AK120 or placebo is administered subcutaneously to healthy subjects
AK120 or placebo- Part 1- Cohort 3Drug
Single dose of 150mg AK120 or placebo is administered subcutaneously to healthy subjects
AK120 or placebo- Part 1- Cohort 4Drug
Single dose of 300mg AK120 or placebo is administered subcutaneously to healthy subjects
AK120 or placebo- Part 1- Cohort 5Drug
Single dose of 600mg AK120 or placebo is administered subcutaneously to healthy subjects
AK120 or placebo- Part 2- Cohort 1Drug
Multiple low doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
AK120 or placebo- Part 2- Cohort 2Drug
Multiple medium doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
AK120 or placebo- Part 2- Cohort 3Drug
Multiple high doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
AK120 or placebo- Part 2- Cohort 4Drug
Multiple high doses of AK120 or placebo are administered subcutaneously as a bi-weekly dose for a total of three doses to subjects with moderate-to-severe atopic dermatitis.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events(AEs)/serious adverse events(SAEs)Time frame: From signing of informed consent through through 12 weeks post-dose
Locations
13 sites in 2 countries. Site status is shown where the registry gives one.
CMAX Clinical Research
Adelaide, Australia
Sinclair Dermatology
East Melbourne, Australia
Peninsula Specialist Centre
Kippa-Ring, Australia
Scientia Clinical Research Ltd
Randwick, Australia
Emeritus Sydney
Botany, New South Wales, Australia
Emeritus Melbourne
Camberwell, Victoria, Australia
Optimal Clinical Trials
Auckland, New Zealand
Christchurch Clinical Studies Trust
Christchurch, New Zealand
Southern Clinical Trials - Christchurch
Christchurch, New Zealand
P3 Research Hawkes Bay
Havelock North, New Zealand
P3 Research Tauranga
Tauranga, New Zealand
P3 Research Wellington
Wellington, New Zealand
Southern Clinical Trials - Waitemata
Birkenhead, Auckland, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.